Blog
Published May 17, 2024
Executive Summary
The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024.
Some key features of the reform plan include:
The creation of premiums for incentivizing the early introduction of new innovative therapies in Japan
The establishment of post-listing price adjustment scheme by average foreign price for specific imported drugs at the time of price revision
The simplification of the price maintenance premium (PMP) system so…
Read Now
Webinars
Available On Demand
Join us for the next webinar in our “Making AI Real” webinar series, where we will focus on practical applications of generative AI for Medical Affairs.Medical Affairs teams are rapidly adopting generative AI to work more efficiently and effectively, although key challenges have begun to emerge. In this webinar, we will explore the best use cases that Medical Affairs teams can (and should) be implementing now to make the greatest impact for their organizations—and how to avoid the common pitfalls…
Watch Now
Webinars
Available On Demand
A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively discussion on the benefits of rapid access to cumulative, compounded learnings generated from in-depth analysis of global HTA recommendations, with presenters Mary Fletcher-Louis, Managing Director…
Watch Now
White Papers
To date, life sciences’ efforts towards driving equitable healthcare have centered around access to care, early identification and prevention. Meanwhile, less attention has been given to the impact of the racial and ethnic homogeneity in trial populations. Clinical trial diversity continues to be one of the greatest challenges pharmaceutical and biotech companies face in ensuring the delivery of medicines that are effective for all people. Diverse clinical trial populations are an integral step in achieving equitable healthcare treatment.
While we…
Read Now
Blog
Published April 30, 2024
Reliable forecast models are a cornerstone of any successful commercialization plan.
The inputs that drive those forecast models are critical.
From 2020 through 2022:
Only
1
in
10
products had performance aligned with forecasted expectations*
Nearly
60% underperformed their forecast expectations
More than
30% overperformed
Forecast models often rely on healthcare professional (HCP)-reported behavioral data.
Various subjective calibration factors are required to render the data usable, even after implementing robust market research design elements.
Data from primary market research (PMR)…
Read Now
Case Studies
Client Situation
The objective was to increase market share of target prescribers through an AI-powered Next Best Action model
Trinity’s Role
We were able to deploy this solution in 3 weeks. The project included:
Discussions with the client team to finalize standardized business rules for brand-agnostic data and KPI definitions
Master dataset development through applying business rules and automated monthly PySpark code refreshes
State-of-the-art machine learning algorithms like reinforcement learning, deep neural networks with dynamic recalibration and automated hyperparameter tuning…
Read Now
Webinars
Available On Demand
Did you know 62% of products launched between September 2019 and December 2021 underperformed expectations in the first year of launch?
What is going wrong, and how can we get it right? Join Trinity Life Sciences for a thought-provoking webinar to dive into the first white paper in our Industry Impact Series, Picking Winners: Portfolio Management for a New Era.
Hear from Trinity’s Leslie Orne, President & CEO, Herman Sanchez, Chief Business Officer and Chad Faulkner, Partner, as they explore the challenges…
Watch Now
Blog
Published April 22, 2024
Executive Summary
The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system.
The 2024 PLFSS emphasizes:
Drug access and cost containment, with a higher payback trigger aimed at reducing the government’s payback collections
Temporary reimbursement to ensure continuous treatment of patients with medicines benefitting from the early…
Read Now
Scientific Publications
Healthcare Resource Utilization of Patients with Short Bowel Syndrome Dependent on Parenteral Support: A Retrospective Claims Analysis
AUTHOR(S): Ali A1, Micic D2, Gallivan M1, Kulkarni A3, Henderson J4, Mitchell G4 1Trinity Life Sciences, Waltham, MA, USA, 2University of Chicago Medical Center, Gastroenterology, Hepatology, and Nutrition, Chicago, IL, USA, 3Trinity Life Sciences, Malden, MA, USA, 4VectivBio AG, Basel, Basel, Switzerland
OBJECTIVES: Short bowel syndrome with intestinal failure (SBS-IF) is a rare, chronic, debilitating malabsorptive condition often caused by massive resection of the…
Read Now
Webinars
Available On Demand
Generative AI (GenAI) has created an opportunity to re-think and significantly improve how we work. Although far from replacing humans, GenAI has the potential to make pharma professionals far more effective and valuable to their organizations. Join us for “Making AI Real,” a webinar series from Trinity Life Sciences dedicated to exploring how to leverage generative AI across different areas within pharmaceutical commercial operations and medical affairs. Our first webinar in this series will be on AI for Insights: discover how generative AI…
Watch Now
